CA3154083A1 - Methods of promoting scfa production by gut microbiota - Google Patents

Methods of promoting scfa production by gut microbiota Download PDF

Info

Publication number
CA3154083A1
CA3154083A1 CA3154083A CA3154083A CA3154083A1 CA 3154083 A1 CA3154083 A1 CA 3154083A1 CA 3154083 A CA3154083 A CA 3154083A CA 3154083 A CA3154083 A CA 3154083A CA 3154083 A1 CA3154083 A1 CA 3154083A1
Authority
CA
Canada
Prior art keywords
methods
promoting
gut microbiota
scfa production
gut
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3154083A
Other languages
English (en)
French (fr)
Inventor
Barry Smith
Michael Butler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Multigerm UK Enterprises Ltd
Original Assignee
Multigerm UK Enterprises Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Multigerm UK Enterprises Ltd filed Critical Multigerm UK Enterprises Ltd
Publication of CA3154083A1 publication Critical patent/CA3154083A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Mycology (AREA)
  • Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Pediatric Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)
CA3154083A 2019-10-18 2020-10-16 Methods of promoting scfa production by gut microbiota Pending CA3154083A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB201915144A GB201915144D0 (en) 2019-10-18 2019-10-18 Method of promoting SCFA production by gut microbiota
GB1915144.8 2019-10-18
PCT/GB2020/052621 WO2021074649A2 (en) 2019-10-18 2020-10-16 Methods of promoting scfa production by gut microbiota

Publications (1)

Publication Number Publication Date
CA3154083A1 true CA3154083A1 (en) 2021-04-22

Family

ID=68728134

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3154083A Pending CA3154083A1 (en) 2019-10-18 2020-10-16 Methods of promoting scfa production by gut microbiota

Country Status (12)

Country Link
US (1) US12419921B2 (https=)
EP (1) EP4044830A2 (https=)
JP (2) JP7809339B2 (https=)
CN (2) CN114745970B (https=)
AU (1) AU2020368684B2 (https=)
BR (1) BR112022007413A2 (https=)
CA (1) CA3154083A1 (https=)
DE (1) DE20796905T1 (https=)
ES (1) ES2922359T1 (https=)
GB (1) GB201915144D0 (https=)
MX (1) MX2022004382A (https=)
WO (1) WO2021074649A2 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201915144D0 (en) * 2019-10-18 2019-12-04 Multigerm Uk Entpr Ltd Method of promoting SCFA production by gut microbiota
CN113875975B (zh) * 2021-09-03 2023-06-30 许昌学院 一种利用小麦加工副产物制备后生元的发酵工艺
WO2024216281A1 (en) * 2023-04-14 2024-10-17 Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for treatment of circadian rhythm disorders
WO2025217259A1 (en) * 2024-04-10 2025-10-16 Postbiotics Plus Research Llc Use of postbiotics for treating or preventing disruptions of the gut-brain axis

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6899872B1 (en) * 1995-11-27 2005-05-31 Standa Lab Sa Absorbable dietary composition for improving the biological balance of intestinal tract flora
GB2418431A (en) * 2004-09-27 2006-03-29 Multigerm Uk Entpr Ltd Metabolically active micro organisms and methods for their production
WO2011060123A1 (en) * 2009-11-12 2011-05-19 Nestec S.A. Nutritional composition for promoting gut microbiota balance and health
US8591412B2 (en) * 2009-11-18 2013-11-26 Nohands, Llc Method and system for preventing virus-related obesity and obesity related diseases
US9707207B2 (en) * 2010-05-26 2017-07-18 The United States Of America As Represented By The Department Of Veterans Affairs Method for diagnosing, preventing, and treating neurological diseases
US10086018B2 (en) * 2011-02-04 2018-10-02 Joseph E. Kovarik Method and system for reducing the likelihood of colorectal cancer in a human being
US10512661B2 (en) 2011-02-04 2019-12-24 Joseph E. Kovarik Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease
US10548761B2 (en) * 2011-02-04 2020-02-04 Joseph E. Kovarik Method and system for reducing the likelihood of colorectal cancer in a human being
US10842834B2 (en) 2016-01-06 2020-11-24 Joseph E. Kovarik Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease
DK3329927T3 (da) * 2011-11-16 2023-12-11 Multigerm Uk Entpr Ltd IBS-behandling med probiotika
GB201219873D0 (en) * 2012-11-05 2012-12-19 Multigerm Uk Entpr Ltd Diverticulitis treatment
US8889633B2 (en) * 2013-03-15 2014-11-18 Mead Johnson Nutrition Company Nutritional compositions containing a peptide component with anti-inflammatory properties and uses thereof
WO2015159125A1 (en) * 2014-04-15 2015-10-22 Compagnie Gervais Danone Use of lactobacillus rhamnosus for promoting recovery of the intestinal microbiota diversity after antibiotic dysbiosis
EP3639834B1 (en) * 2016-02-04 2023-07-12 Universiteit Gent Use of microbial communities for human and animal health
US10055534B2 (en) * 2016-03-17 2018-08-21 Applied Materials Israel Ltd. System and method for design based inspection
PL3443071T3 (pl) * 2016-04-11 2022-03-28 Wageningen Universiteit Nowe gatunki bakterii
US20180357375A1 (en) 2017-04-04 2018-12-13 Whole Biome Inc. Methods and compositions for determining metabolic maps
US11730749B2 (en) 2017-05-05 2023-08-22 Plexus Worldwide, Llc Compositions and methods for improving gut health
AU2018313765A1 (en) 2017-08-07 2020-02-27 Finch Therapeutics, Inc. Compositions and methods for decolonizing antibotic-resistant bacteria in the gut
AU2019216129B2 (en) * 2018-02-02 2022-03-17 Kobiolabs, Inc. Lactobacillus plantarum KBL396 strain and use thereof
GB201915144D0 (en) * 2019-10-18 2019-12-04 Multigerm Uk Entpr Ltd Method of promoting SCFA production by gut microbiota
FR3136482A1 (fr) * 2021-08-01 2023-12-15 Snipr Biome Aps Ingenierie du microbiote

Also Published As

Publication number Publication date
ES2922359T1 (es) 2022-09-13
GB201915144D0 (en) 2019-12-04
US20230053778A1 (en) 2023-02-23
MX2022004382A (es) 2022-08-25
DE20796905T1 (de) 2022-11-24
AU2020368684A1 (en) 2022-05-19
CN114745970A (zh) 2022-07-12
JP2025163045A (ja) 2025-10-28
WO2021074649A2 (en) 2021-04-22
JP2022553017A (ja) 2022-12-21
BR112022007413A2 (pt) 2022-07-05
CN118593548A (zh) 2024-09-06
AU2020368684B2 (en) 2026-02-12
JP7809339B2 (ja) 2026-02-02
US12419921B2 (en) 2025-09-23
WO2021074649A3 (en) 2021-07-22
EP4044830A2 (en) 2022-08-24
CN114745970B (zh) 2024-06-21

Similar Documents

Publication Publication Date Title
CA3154083A1 (en) Methods of promoting scfa production by gut microbiota
EP3954395A4 (en) Pharmaceutical composition for muscle disease treatment
EP4631944A3 (en) Rimegepant for cgrp related disorders
EP4596041A3 (en) Farnesoid x receptor agonists and uses thereof
PH12019502782A1 (en) Fixed dose formulations
WO2018060732A3 (en) Compositions and methods for treating seizure disorders
WO2017087608A8 (en) Modulators of ror-gamma
MX2021004110A (es) Composiciones farmaceuticas que comprenden n-(3,5- dimetoxifenil)-n'-(1-metiletil)-n-[3-(1-metil-1h- pirazol-4-il)quinoxalin-6-il]etano-1,2-diamina.
WO2017053868A8 (en) C4-modified oleanolic acid derivatives for inhibition of il-17 and other uses
HK1206297A1 (en) Pharmaceutical compositions for combination therapy
WO2010048332A3 (en) Compounds for treating ophthalmic diseases and disorders
WO2017132432A8 (en) Benzimidazole derivatives as modulators of ror-gamma
WO2011044506A3 (en) Sulphone compounds for use in the treatment of obesity
WO2012051318A8 (en) Sulphonamide compounds and methods of making and using same
HK1247856A1 (zh) 羟丙基β-环糊精组合物及方法
EP4417261A3 (en) Bacteriotherapy
WO2017062468A8 (en) Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof
WO2008097924A3 (en) Pharmaceutical compositions comprising dextromethorphan analogs for the treatment of neurological disorders
WO2016130800A3 (en) Pharmaceutical compositions comprising perillyl alcohol derivatives
CA2986891C (en) Compositions for use in treating parkinson's disease and related disorders
WO2020127819A3 (en) Pharmaceutical composition comprising apixaban
WO2018005801A3 (en) Novel non-systemic tgr5 agonists
WO2008157747A8 (en) Use of inhibition of exonuclease 1 in methods for therapy and diagnostic of neurodegenerative diseases, eye diseases, and mitochondrial disorders
WO2016168553A8 (en) Deuterated obeticholic acid
WO2018005794A3 (en) Novel non-systemic tgr5 agonists

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220928

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241011

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241011

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241011

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250203

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250602

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250604

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250609

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250609

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250930

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250930

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260326

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260326